More than 1,000 different drugs are thought to cause liver damage and one French study estimated the global annual incidence rate of drug-related liver damage as 8 cases per 100,000 inhabitants ...

Mirum Pharmaceuticals' promising pipeline and strong financials make it an attractive buy in the competitive PBC space. Click ...

The adverse events from TMZ therapy are often haematologic. Nonetheless, there are rare instances of clinically significant cholestatic liver injury.1 2 There have been reported cases of LEV-induced ...

The declining ability of many boys and men to compete at school and in the workplace has become both a social and a political ...

The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor ...

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid ...

The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients ...

(Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted ...

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte ...

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.